Alan Sabirsh-澳门在线赌城娱乐

I have a broad experience in drug discovery within AstraZeneca having worked across several therapeutic areas since 1990. For more than a decade, my focus has been on robotic microscopy and high-content biology, and I’ve established several laboratories based on these methods.

I joined Pharmaceutical Sciences in 2017 to bring biological insight to cellular delivery of novel chemical modalities, such as modified mRNA, using advanced nano-formulations.

I have established bioscience and high-throughput methods and improved our data science capabilities using automation and AI-assisted data acquisition and analysis.

My publication record includes more than 25 peer-reviewed articles, and I have worked in close collaboration with McMaster University in Canada and Lund University and the Karolinska Institute in Sweden.

There are various proteins involved in disease that conventional molecules can’t target. We refer to them as ‘undruggable’. By using new drug modalities which recognise the genetic sequence, and nanotechnology to deliver them directly to the site, we open whole new possibilities for treatment

Alan Sabirsh Principal Scientist, Advanced Drug Delivery, Pharmaceutical Sciences, R&D

2018

Formed the Intracellular Drug Delivery unit within Pharmaceutical Sciences to study nanomedicines mechanistically from a biological perspective.

2014

Founded the current high content biology unit in Gothenburg, implemented global informatics streams for image analysis and ran the first machine learning analysis of histological samples.

2008

Established central nervous system and pain high content biology unit for robotic cytometric imaging and analysis in Södertälje.

Featured publications

Single-cell transcriptome profiling of human pancreatic islets in health and type 2 diabetes

The leukotriene B4 receptor functions as a novel type of coreceptor mediating entry of primary HIV-1 isolates into CD4-positive cells.

Leukotriene B4 triggers release of the cathelicidin LL-37 from human neutrophils: novel lipid-peptide interactions in innate immune responses.

Long-term chronic toxicity testing using human pluripotent stem cell–derived hepatocytes.

First and second generation γ-secretase modulators (GSMs) modulate amyloid-β (Aβ) peptide production through different mechanisms.

Role of B cell–activating factor (BAFF) in chronic obstructive pulmonary disease.

Leukotriene B4 is the functional ligand binding to and activating the cloned chemoattractant receptor, CMKRL1.

Pro‐and anti‐inflammatory substances modulate expression of the leukotriene B4 receptor, BLT1, in human monocytes. Pettersson et al.

First-generation monoclonal antibodies identifying the human leukotriene B4 receptor-1 Pettersson et al.

Residues from Transmembrane Helices 3 and 5 Participate in Leukotriene B4 Binding to BLT1.